The world raced to develop vaccines to protect against the rapid spread of SARS-CoV-2
infection upon the recognition of COVID-19 as a global pandemic. A broad spectrum of …

Adjuvants are critical for improving the quality and magnitude of adaptive immune responses
to vaccination. Lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA …

The spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates
the development of a rapidly scalable vaccine. Here, we present a self-amplifying RNA …

Lipid nanoparticles (LNP) are the leading systems for in vivo delivery of small interfering
RNA (siRNA) for therapeutic applications. Formulation of LNP siRNA systems requires rapid …

Most known pathogenic point mutations in humans are C•G to T•A substitutions, which can be
directly repaired by adenine base editors (ABEs). In this study, we investigated the efficacy …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein acquired
a D614G mutation early in the pandemic that confers greater infectivity and is now the …

SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high
transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19…

The protective efficacy of serum antibodies results from the interplay of antigen-specific B
cell clones of different affinities and specificities. These cellular dynamics underlie serum-level …

Lipid nanoparticles (LNPs) encapsulating short interfering RNAs that target hepatic genes
are advancing through clinical trials, and early results indicate the excellent gene silencing …

Lipid nanoparticles (LNP) can provide a clinically effective method for delivering small interfering
RNA (siRNA) to silence pathological genes in hepatocytes. The gene silencing potency …